RegenXBio stock kpis
Want to see RGNX full AI Analyst Report?
Revenue by Segment
In Q3 2026, RegenXBio reported revenue by segment of $5.24M (Zolgensma Royalties).
Analyzes income from different business units, highlighting which segments drive growth and profitability, and indicating potential areas for strategic focus or improvement.
Revenue is lumpy and milestone-driven: steady Zolgensma royalties historically provided a recurring base but collapsed in early‑2026, while licensing receipts (a large Nippon Shinyaku payment in 2025 and the $100M AbbVie milestone recognized in Q2‑2026) create outsized spikes. Management’s call confirms the AbbVie milestone; investors should treat near-term revenue as milestone-dependent and focus on sustainability of royalties, timing of future milestones, and regulatory risk that could delay expected cashflow from upcoming approvals.
RGNX Revenue by Segment
| Period | Zolgensma Royalties | Other License and Royalty | Nippon Shinyaku Licenses |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | $5.24M | $0.00 | $0.00 |
| Q2 2026Jun 30, 2026 | $3.84M | $100.00M | $0.00 |
| Q1 2026Mar 31, 2026 | $5.05M | $38.00K | $0.00 |
| Q4 2025Dec 31, 2025 | $24.18M | -$2.09M | $204.00K |
| Q3 2025Sep 30, 2025 | $23.59M | $19.00K | $0.00 |
| Q2 2025Jun 30, 2025 | $18.42M | $216.00K | $2.72M |
| Q1 2025Mar 31, 2025 | $16.99M | $2.04M | $69.98M |
| Q4 2024Dec 31, 2024 | $20.66M | $558.00K | $0.00 |
| Q3 2024Sep 30, 2024 | $23.87M | $325.00K | $0.00 |
| Q2 2024Jun 30, 2024 | $21.76M | $532.00K | $0.00 |
| Q1 2024Mar 31, 2024 | $15.21M | $408.00K | $0.00 |
| Q4 2023Dec 31, 2023 | $21.86M | $348.00K | $0.00 |
| Q3 2023Sep 30, 2023 | $28.36M | $550.00K | $0.00 |
| Q2 2023Jun 30, 2023 | $18.96M | $1.01M | $0.00 |
| Q1 2023Mar 31, 2023 | $16.13M | $3.01M | $0.00 |
| Q4 2022Dec 31, 2022 | $26.79M | $4.56M | $0.00 |
| Q3 2022Sep 30, 2022 | $25.20M | $1.31M | $0.00 |
| Q2 2022Jun 30, 2022 | $28.39M | $4.26M | $0.00 |
| Q1 2022Mar 31, 2022 | $21.54M | $679.00K | $0.00 |
| Q4 2021Dec 31, 2021 | $28.03M | $622.00K | $0.00 |
| Q3 2021Sep 30, 2021 | $30.25M | $519.00K | $0.00 |
| Q2 2021Jun 30, 2021 | $18.43M | $3.61M | $0.00 |
| Q1 2021Mar 31, 2021 | $18.26M | $621.00K | $0.00 |

